New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage).; imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).;   - powder for infusion - 500mg/500mg - active: cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage). imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).   excipient: sodium bicarbonate

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cilastatin, imipenem - powder for solution for infusion - cilastatin 500 mg imipenem 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

hospira uk limited - cilastatin; imipenem - powder for solution for infusion - cilastatin 500 mg; imipenem 500 mg - antibacterials for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cilastatin sodium 530.7mg equivalent to 500 mg cilastatin; imipenem monohydrate 530.1mg equivalent to 500 mg imipenem - powder for injection - 500mg/500mg - active: cilastatin sodium 530.7mg equivalent to 500 mg cilastatin imipenem monohydrate 530.1mg equivalent to 500 mg imipenem excipient: sodium bicarbonate - indicated for the treatment of the following infections due to susceptible organisms: · intra-abdominal infections · lower respiratory tract infections · gynaecological infections · septicaemia · genitourinary tract infections · bone and joint infections · skin and soft tissue infections · endocarditis indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. the majority of these mixed infections are associated with contamination by faecal flora or flora originating from the vagina, skin and mouth. in these mixed infections, bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, ephalosporins and penicillins. however, bacteroides fragilis is usually susceptible to imipenem and cilastatin combination. imipenem and cilastatin combination has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-g, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment imipenem and cilastatin. imipenem+cilastatin rbx is not indicated for the treatment of meningitis.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w), piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx) - piperacillin and tazobactam for injection is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a β-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the conditions listed below. appendicitis (complicated by rupture or abscess) and peritonitis caused by β-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis, b. ovatus, b. thetaiotaomicron, or b. vulgatus .  the individual members of this group were studied in fewer than 10 cases. uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by β-lactamase producing isolates of staphylococcus aureus . postpartum endometritis or pelvic inflammatory disease caused by β-lacta

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - cilastatin sodium 530 mg - eq. cilastatin 500 mg; imipenem monohydrate 530 mg - eq. imipenem 500 mg - powder for solution for infusion - 500 mg - 500 mg - cilastatin sodium; imipenem monohydrate 530 mg - imipenem and enzyme inhibitor

Malta - English - Medicines Authority

apta medica internacional d.o.o likozarjeva ulica 6, 1000 ljubljana, , slovenia - imipenem, cilastatin - powder for solution for infusion - imipenem 500 mg cilastatin 500 mg - antibacterials for systemic use

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

Canada - English - Health Canada

sun pharma canada inc - imipenem; cilastatin (cilastatin sodium) - powder for solution - 250mg; 250mg - imipenem 250mg; cilastatin (cilastatin sodium) 250mg - carbapenems

Canada - English - Health Canada

sun pharma canada inc - imipenem; cilastatin (cilastatin sodium) - powder for solution - 500mg; 500mg - imipenem 500mg; cilastatin (cilastatin sodium) 500mg - carbapenems